Work

Safety and immunogenicity of inactivated Zika virus vaccine by gamma irradiation

Year: 2025

Type: article

Abstract: Developing the Zika virus (ZIKV) vaccine remains a critical global public health need. This study assessed the safety and immunogenicity of gamma-irradiated Thai ZIKV isolate. Inactivation was confirmed by serial passaging and detection of viral replication using RT-PCR, which demonstrated complete loss of infectivity in ZIKV irradiated with 25 and 50 kGy. Western blotting confirmed that irradiation preserved viral envelope protein antigenicity. BALB/c mice were subcutaneously immunized twice with 25 kGy-irradiated ZIKV, either alone or with alum adjuvant, at two-week intervals. No mortality or local reactions were observed in any group of mice. Antigen-specific IgG and neutralizing antibody titers were measured by ELISA and focus reduction neutralization test, respectively. T cell responses were assessed via intracellular IFN-γ and TNF-α staining by flow cytometry. The irradiated vaccine induced ZIKV-specific antibody and cytokine-producing T cell responses; however, neutralizing antibody titers were low. Mice immunized with irradiated ZIKV combined with alum adjuvant had higher ZIKV-specific antibody titers and T cells producing IFN-γ or TNF-α than those without adjuvant, though differences were not statistically significant. Although the viral integrity and antigenicity remained unchanged, these findings demonstrate that gamma-irradiated ZIKV is non-infectious and immunogenic in mice, supporting its safety profile and the potential for further optimization in future dose-ranging and efficacy studies. • Gamma-irradiation at 25 kGy fully inactivated ZIKV while preserving antigenicity. • Gamma-irradiated ZIKV vaccine was safe and immunogenic in BALB/c mice. • Alum adjuvant enhanced ZIKV-specific antibody and T-cell responses. Gamma-irradiation is a promising method for inactivated ZIKV vaccine development.

Source: Vaccine X

DOI: 10.1016/j.jvacx.2025.100706